Image Credit: Biotronik
On June 8, 2026, Biotronik announced the first U.S. implant of its LivIQ leadless pacemaker as part of the BIO-LivIQ global pivotal clinical trial. The device uses a novel far-field sensing scheme to electrically detect atrial activity and thus enable a single-device VDD mode. According to Biotronik, this sensing approach supports AV synchrony across a broad range of clinical scenarios.
Additionally, LivIQ features a highly maneuverable catheter designed to provide precise control and predictable placement within the RV.
The BIO-LivIQ study will enroll 325 patients across 60 sites worldwide. The trial will evaluate device safety, pacing performance, AV-synchrony behavior, and quality-of-life outcomes to generate the evidence required for global regulatory submissions.